Rituximab used to treat recalcitrant noninfectious scleritis

Rituximab, with and without additional immunomodulatory therapy, resulted in steroid-free remission of recalcitrant noninfectious scleritis in a majority of patients in one study. The retrospective case series included 24 eyes of 15 patients with clinically diagnosed noninfectious scleritis who underwent rituximab infusion in accordance with varying treatment protocols. A rheumatologic protocol was implemented in eight patients, an oncologic protocol was implemented in three patients, and the Foster ocular inflammatory disease protocol was implemented in four patients. A mean of three immunomodulatory interventions had been tried and failed in the group of patients before inclusion in the study.